Grossman Adam S 4

What Happened
Adam S. Grossman, President, CEO and Director of ADMA Biologics, received equity awards on February 9, 2026: 282,529 restricted stock units (RSUs) reported as an award (price $0) and 444,711 RSU-related derivative units reported separately. These RSUs are unvested awards that will settle into common stock upon vesting; no cash was paid for the grants.

Key Details

• Transaction date: 2026-02-09; Form 4 filed 2026-02-11 (timely).
• Reported entries: 282,529 RSUs (Award, A) and 444,711 RSU-related derivative units (A); transaction price shown as $0.00.
• Vesting: New RSUs vest quarterly over four years from grant date (per the ADMA 2022 Equity Compensation Plan). All listed RSUs settle into common stock upon vesting.
• Shares owned after transaction: 975,684 shares of common stock (reported) plus approximately 1,314,695 unvested RSUs across grants (breakdown by grant year in filing: 282,529 ^[2026], 252,022 ^[2025], 418,296 [2024 portion], 286,848 [2023 portion], 75,000 [2022 portion]).
• Related roles/ownership: Grossman is a control person of Areth, LLC and managing member of Hariden, LLC (both referenced in footnotes as holders of company shares).
• Options note: The filing also references outstanding options that vest over four years (25% after one year, then monthly), becoming fully vested on Feb 9, 2030.
• Filing status: Timely (no late filing indicated).

Context
This was an equity award (RSUs), not an open-market purchase or sale—awards are common compensation for executives and do not represent an immediate cash purchase or sale. RSUs are derivative securities that convert to shares only as they vest; they can signal continued alignment with shareholders but do not by themselves indicate buying or selling intent.